Technical Data
Interferon, beta, neutralizing (Interferon beta, IFN-beta, Fibroblast Interferon, IFB, IFNB)
interferon beta (IFN Beta), a 22kD cytokine with wide-ranging antiviral, antimicrobial and antitumor effects. Interferons also serve to activate macrophages, natural killer cells and the presentation of antigens to the immune system by the major histocompatibility complex. The production of interferon is induced in response to microbes and other cytokines. The interferons are widely used to treat a variety of diseases and IFNB in particular is used to treat relapsing-remitting multiple sclerosis.

Suitable for use in ELISA, Western Blot, Immunoprecipitation, Immunohistochemistry and Neutralization. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Biological Activity:
2 x 10e4 Units at 1.12 x 10e5 Neutralization Units/ml.

Unit Definition:
One neutralization unit is the amount of antiserum required to neutralize 1 unit of mouse IFN-beta. This material is prepared specifically for effective neutralization of mouse IFN-beta.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
100ul-20CBlue IceMouseRabbit
Not determined.
Linear peptide corresponding to the internal domain of mouse Interferon beta, conjugated to KLH.
Supplied as a liquid.
Recognizes mouse IFN-b at ~18kD.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Rosati, S., et al. (2008). Molecular Cancer Ther. 7:3852-3858. 2. Davidoff, A., et al. (2007). Mol. Cancer Res. 5:531-542. 3. Vitale, G., et al. (2006). Cancer Research. 66: 554-562.4.. Deonarain, R., et al. (2003). PNAS. 100(23): 13453-13458.5. Vieillard, V., et al. (1997). PNAS. 94(21): 11595-11600.6. Rubinstein S. F., et al. (1981). Journal of Virology. 37:755-758.